Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia

Molecular Therapy

Volumn 23, Issue 1, 2015, Pages 184-191

  Wang, Quan Shun ^a   Wang, Yao ^a   Lv, Hai Yan ^a   Han, Qing Wang ^a   Fan, Hui ^a   Guo, Bo ^a   Wang, Li Li ^a   Han, Wei Dong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; CD33 PROTEIN, HUMAN; CHIMERIC PROTEIN; CYTOKINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER RESISTANCE; CASE REPORT; CELL EXPANSION; CELL MEDIATED CYTOTOXICITY; CELL THERAPY; CHILL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; FEASIBILITY STUDY; FEVER; HUMAN; HYPERBILIRUBINEMIA; LEUKEMIA RELAPSE; MALE; PANCYTOPENIA; PATIENT SAFETY; T LYMPHOCYTE; TREATMENT RESPONSE; ADOPTIVE TRANSFER; AUTOTRANSPLANTATION; BIOSYNTHESIS; GENE EXPRESSION; GENE VECTOR; GENETICS; HL 60 CELL LINE; IMMUNOLOGY; K562 CELL LINE; LEUKEMIA, MYELOID, ACUTE; PATHOLOGY; RECURRENT DISEASE; TRANSPLANTATION;

ADOPTIVE TRANSFER; ADULT; CYTOKINES; GENE EXPRESSION; GENETIC VECTORS; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTANT CHIMERIC PROTEINS; RECURRENCE; SIALIC ACID BINDING IG-LIKE LECTIN 3; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS;

EID: 84920693049     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.164     Document Type: Article

References (34)

1. Döhner, H, Estey, EH, Amadori, S, Appelbaum, FR, Büchner, T, Burnett, AK, Dombret, H et al.; European LeukemiaNet. (2010). Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115: 453-474.
2. Creutzig, U, van den Heuvel-Eibrink, MM, Gibson, B, Dworzak, MN, Adachi, S, de Bont, E, Harbott, J et al.; AML Committee of the International BFM Study Group. (2012). Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 120: 3187-3205.
3. Tettamanti, S, Magnani, CF, Biondi, A and Biagi, E (2013). Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modifed immune effectors. Immunol Lett 155: 43-46.
4. Pearce, DJ, Taussig, D, Zibara, K, Smith, LL, Ridler, CM, Preudhomme, C, Young, BD et al. (2006). AML engraftment in the NOD/SCID assay refects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 107: 1166-1173.
5. Nakahata, T and Okumura, N (1994). Cell surface antigen expression in human erythroid progenitors: erythroid and megakaryocytic markers. Leuk Lymphoma 13: 401-409.
6. Taussig, DC, Pearce, DJ, Simpson, C, Rohatiner, AZ, Lister, TA, Kelly, G, Luongo, JL et al. (2005). Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106: 4086-4092.
7. Griffn, JD, Linch, D, Sabbath, K, Larcom, P and Schlossman, SF (1984). A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 8: 521-534.
8. Dinndorf, PA, Andrews, RG, Benjamin, D, Ridgway, D, Wolff, L and Bernstein, ID (1986). Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 67: 1048-1053.
9. Kung Sutherland, MS, Walter, RB, Jeffrey, SC, Burke, PJ, Yu, C, Kostner, H, Stone, I et al. (2013). SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122: 1455-1463.
10. Nand, S, Othus, M, Godwin, JE, Willman, CL, Norwood, TH, Howard, DS, Coutre, SE et al. (2013). A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood 122: 3432-3439.
11. Rowe, JM and Löwenberg, B (2013). Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood 121: 4838-4841.
12. Hinrichs, CS and Rosenberg, SA (2014). Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 257: 56-71.
13. Grupp, SA, Kalos, M, Barrett, D, Aplenc, R, Porter, DL, Rheingold, SR, Teachey, DT et al. (2013). Chimeric antigen receptor-modifed T cells for acute lymphoid leukemia. N Engl J Med 368: 1509-1518.
14. Kalos, M, Levine, BL, Porter, DL, Katz, S, Grupp, SA, Bagg, A et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3: 95ra73.
15. Kochenderfer, JN, Dudley, ME, Feldman, SA, Wilson, WH, Spaner, DE, Maric, I, Stetler-Stevenson, M et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709-2720.
16. Dutour, A, Marin, V, Pizzitola, I, Valsesia-Wittmann, S, Lee, D, Yvon, E, Finney, H et al. (2012). In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. Adv Hematol 2012: 683065.
17. Marin, V, Pizzitola, I, Agostoni, V, Attianese, GM, Finney, H, Lawson, A, Pule, M et al. (2010). Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specifc chimeric receptors. Haematologica 95: 2144-2152.
18. Pizzitola, I, Anjos-Afonso, F, Rouault-Pierre, K, Lassailly, F, Tettamanti, S, Spinelli, O, Biondi, A et al. (2014). Chimeric antigen receptors against CD33/CD123 antigens effciently target primary acute myeloid leukemia cells in vivo. Leukemia 28: 1596-1605.
19. Sievers, EL, Larson, RA, Stadtmauer, EA, Estey, E, Löwenberg, B, Dombret, H, Karanes, C et al.; Mylotarg Study Group. (2001). Effcacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in frst relapse. J Clin Oncol 19: 3244-3254.
20. Kharfan-Dabaja, MA, Hamadani, M, Reljic, T, Pyngolil, R, Komrokji, RS, Lancet, JE, Fernandez, HF et al. (2013). Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 163: 315-325.
21. Wang, Y, Bo, J, Dai, HR, Lu, XC, Lv, HY, Yang, B, Wang, T et al. (2013). CIK cells from recurrent or refractory AML patients can be effciently expanded in vitro and used for reduction of leukemic blasts in vivo. Exp Hematol 41: 241-252.e3.
22. Laszlo, GS, Estey, EH and Walter, RB (2014). The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev 28: 143-153.
23. McKoy, JM, Angelotta, C, Bennett, CL, Tallman, MS, Wadleigh, M, Evens, AM, Kuzel, TM et al. (2007). Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 31: 599-604.
24. Larson, RA, Sievers, EL, Stadtmauer, EA, Löwenberg, B, Estey, EH, Dombret, H, Theobald, M et al. (2005). Final report of the effcacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in frst recurrence. Cancer 104: 1442-1452.
25. Maniecki, MB, Hasle, H, Bendix, K and Møller, HJ (2011). Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specifc targeting of hepatocytes? Leuk Res 35: e84-e86.
26. Nishimura, R, Baker, J, Beilhack, A, Zeiser, R, Olson, JA, Sega, EI, Karimi, M et al. (2008). In vivo traffcking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 112: 2563-2574.
27. Hernández-Caselles, T, Martínez-Esparza, M, Pérez-Oliva, AB, Quintanilla-Cecconi, AM, García-Alonso, A, Alvarez-López, DM et al. (2006). A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J Leukoc Biol 79: 46-58.
28. Hauswirth, AW, Florian, S, Printz, D, Sotlar, K, Krauth, MT, Fritsch, G, Schernthaner, GH et al. (2007). Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest 37: 73-82.
29. Cowan, AJ, Laszlo, GS, Estey, EH and Walter, RB (2013). Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark Ed) 18: 1311-1334.
30. Jedema, I, Barge, RM, van der Velden, VH, Nijmeijer, BA, van Dongen, JJ, Willemze, R et al. (2004). Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for effcacy in CD33-negative malignancies with endocytic capacity. Leukemia 18: 316-325.
31. Landau, DA, Carter, SL, Getz, G and Wu, CJ (2014). Clonal evolution in hematological malignancies and therapeutic implications. Leukemia 28: 34-43.
32. Zeijlemaker, W, Gratama, JW and Schuurhuis, GJ (2014). Tumor heterogeneity makes AML a "moving target" for detection of residual disease. Cytometry B Clin Cytom 86: 3-14.
33. Introna, M, Borleri, G, Conti, E, Franceschetti, M, Barbui, AM, Broady, R, Dander, E et al. (2007). Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 92: 952-959.
34. Linn, YC, Niam, M, Chu, S, Choong, A, Yong, HX, Heng, KK, Hwang, W et al. (2012). The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant 47: 957-966.